JP7246125B2 - Epidermal cell activator - Google Patents
Epidermal cell activator Download PDFInfo
- Publication number
- JP7246125B2 JP7246125B2 JP2016213669A JP2016213669A JP7246125B2 JP 7246125 B2 JP7246125 B2 JP 7246125B2 JP 2016213669 A JP2016213669 A JP 2016213669A JP 2016213669 A JP2016213669 A JP 2016213669A JP 7246125 B2 JP7246125 B2 JP 7246125B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- growth factor
- epidermal cell
- epidermal
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を有効成分とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤に関する。 The present invention relates to an epidermal cell activator, an epidermal growth factor production promoter, and an epidermal growth factor receptor production promoter containing one or two selected from purple extract and valerian extract as active ingredients.
顔や背中や手足などの紫外線に暴露された部分では老化が進み、局部的な色素沈着、いわゆる「シミ」が形成されてくる。シミの形成メカニズムとしては、紫外線や老化などの刺激によるメラニン生成の亢進と転送されたメラニンの排泄のバランスが崩れたものがシミとなって現れてくると言われている。そこで、美白剤に応用されるアプローチとしては、亢進されたメラニン生成を抑える手法と後退したメラニン排泄を回復させる方法が考えられる。これまでに前者のメラニン生成を抑える美白剤の研究は多数なされてきたが、後者のメラニン排泄を回復、促進させる美白剤の研究はあまり行われてこなかった(非特許文献1)。 Areas exposed to ultraviolet rays, such as the face, back, and hands and feet, progress in aging, and localized pigmentation, so-called "blemishes", is formed. As for the formation mechanism of spots, it is said that spots appear when the balance between the enhancement of melanin production due to stimuli such as ultraviolet rays and aging and the excretion of transferred melanin is disturbed. Therefore, as an approach applied to skin-whitening agents, a method of suppressing the accelerated melanin production and a method of restoring the regressed melanin excretion are conceivable. Many studies have been conducted so far on whitening agents that suppress the former melanin production, but little research has been conducted on whitening agents that restore and promote the latter melanin excretion (Non-Patent Document 1).
かかる老化症状を防止するため、表皮細胞成長因子(EGF)の産生を促進する成分として、ゴマの抽出物、ジオウの抽出物、モモの抽出物、カンゾウの抽出物、ドクダミの抽出物、サボテンの抽出物、コムギ胚芽の抽出物、キャッツクローの抽出物、シソの抽出物、ビワの抽出物が知られている(特許文献1)。 In order to prevent such aging symptoms, sesame extract, rhubarb extract, peach extract, licorice extract, Houttuynia cordata extract, and cactus extract are used as ingredients that promote the production of epidermal growth factor (EGF). An extract, a wheat germ extract, a cat's claw extract, a perilla extract, and a loquat extract are known (Patent Document 1).
また、表皮細胞成長因子は、その受容体(表皮細胞成長因子受容体、EGFR)によって細胞内に取り込まれて初めてその効果を発揮することが知られている(特許文献2)。 It is also known that epidermal growth factor exerts its effects only after it is taken up into cells by its receptor (epidermal growth factor receptor, EGFR) (Patent Document 2).
これまで、表皮細胞成長(EGF)産生促進作用と、表皮細胞成長促進因子受容体(EGFR)産生促進作用を併せ持つ成分に関する研究はなされてこなかった。EGF産生促進作用とEGFR産生促進作用を兼ね備えることにより、老化等により引き起こされた表皮細胞のターンオーバーを活性化し、くすみや皮膚老化状態を予防する老化防止効果及び美肌効果を発現し、皮膚を健やかに保つことのできる、表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤、を提供することを課題とする。 So far, no studies have been made on ingredients having both epidermal cell growth (EGF) production-promoting action and epidermal growth factor receptor (EGFR) production-promoting action. By combining the EGF production promotion action and the EGFR production promotion action, the turnover of epidermal cells caused by aging etc. is activated, and the anti-aging effect and skin beautifying effect that prevent dullness and skin aging are expressed, and the skin is healthy. An object of the present invention is to provide an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter, which can maintain the
本発明は、ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を有効成分とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤、を提供する。 The present invention provides an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter containing one or two selected from purple extract and valerian extract as active ingredients. do.
ムラサキ抽出物、カノコソウ抽出物は、高い表皮細胞賦活効果、表皮細胞成長因子産生促進効果、表皮細胞成長因子受容体産生促進効果を発揮し、くすみや皮膚老化状態を予防する老化防止作用及び美肌作用を発現し、皮膚を健やかに保つことができる。 Murasaki extract and valerian extract exhibit high epidermal cell activating effect, epidermal cell growth factor production promoting effect, and epidermal cell growth factor receptor production promoting effect, and anti-aging and skin beautifying effects to prevent dullness and skin aging. can be expressed and the skin can be kept healthy.
以下本発明を実施するための形態を説明する。 A mode for carrying out the present invention will be described below.
本発明で使用するムラサキ抽出物は、ムラサキ(Lithospermum officinale)の根を用いる。 The purple extract used in the present invention uses the root of purple (Lithospermum officinale).
本発明で使用するカノコソウ抽出物は、カノコソウ(Valeriana fauriei)の、葉、茎、花、根等の各部位および全草を用いることができるが、根、根茎を用いることが好ましい。 Valeriana fauriei extracts used in the present invention can be the leaves, stems, flowers, roots and other parts of valeriana fauriei and the whole plant, but preferably the roots and rhizomes.
本発明において、上記各植物抽出物は生のまま抽出に供してもよいが、抽出効率を考えると、細切,乾燥,粉砕等の処理を行った後に抽出を行うことが好ましい。抽出は、抽出溶媒に浸漬して行う。抽出効率を上げるため撹拌を行ったり、抽出溶媒中でホモジナイズしてもよい。抽出温度としては、5℃程度から抽出溶媒の沸点以下の温度とするのが適切である。抽出時間は抽出溶媒の種類や抽出温度によっても異なるが、4時間~14日間程度とするのが適切である。 In the present invention, each of the above plant extracts may be used for extraction in its raw state, but in consideration of extraction efficiency, it is preferable to perform extraction after treatment such as chopping, drying, and pulverization. Extraction is performed by immersion in an extraction solvent. Stirring or homogenization in an extraction solvent may be performed to increase extraction efficiency. A suitable extraction temperature is from about 5° C. to a temperature below the boiling point of the extraction solvent. Although the extraction time varies depending on the type of extraction solvent and the extraction temperature, it is suitable to be about 4 hours to 14 days.
抽出溶媒としては、水の他、メタノール,エタノール,プロパノール,イソプロパノール等の低級アルコール、1,3-ブチレングリコール,プロピレングリコール,ジプロピレングリコール,グリセリン等の多価アルコール、エチルエーテル,プロピルエーテル等のエーテル類、酢酸エチル,酢酸ブチル等のエステル類、アセトン,エチルメチルケトン等のケトン類などの極性有機溶媒を用いることができ、これらより1種又は2種以上を選択して用いる。また、生理食塩水,リン酸緩衝液,リン酸緩衝生理食塩水等を用いてもよい。 Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, and ethers such as ethyl ether and propyl ether. , esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone. Physiological saline, phosphate buffer, phosphate buffered saline, etc. may also be used.
上記植物の上記溶媒による抽出物は、そのままでも本発明に係る組成物に含有させることができるが、濃縮,乾固したものを水や極性溶媒に再度溶解したり、或いはそれらの皮膚生理機能向上作用を損なわない範囲で脱色,脱臭,脱塩等の精製処理を行ったり、カラムクロマトグラフィーによる分画処理を行った後に用いてもよい。また保存のため、精製処理の後凍結乾燥し、用時に溶媒に溶解して用いることもできる。また、リポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。 The extract of the above-mentioned plant with the above-mentioned solvent can be contained in the composition according to the present invention as it is. It may be used after purification treatment such as decolorization, deodorization, and desalting, or fractionation treatment by column chromatography, as long as the action is not impaired. For storage, it can also be freeze-dried after purification and dissolved in a solvent before use. It can also be used by encapsulating it in vesicles such as liposomes or microcapsules.
特にリポソーム等のベシクルやマイクロカプセル等に内包させて用いることにより、経皮吸収が高まり、より高い効果を発揮する。 In particular, by encapsulating it in vesicles such as liposomes, microcapsules, or the like, percutaneous absorption is enhanced and higher effects are exhibited.
ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種は、優れた表皮細胞賦活効果、表皮細胞成長因子産生促進効果、表皮細胞成長因子受容体産生促進効果を有し、表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤として利用することができる。 One or two selected from purple extract and valerian extract have excellent epidermal cell activating effect, epidermal cell growth factor production promoting effect, and epidermal cell growth factor receptor production promoting effect. , epidermal growth factor production promoter, and epidermal growth factor receptor production promoter.
ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を含有することを特徴とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤は、単独でも使用することができるが、表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤として医薬品、医薬部外品、飲食品、化粧品などの種々の組成物に配合することにより、表皮細胞賦活作用、表皮細胞成長因子産生促進作用、表皮細胞成長因子受容体産生促進作用を有する組成物を得ることができる。 The epidermal cell activator, epidermal cell growth factor production promoter, and epidermal cell growth factor receptor production promoter characterized by containing one or two selected from purple extract and valerian extract can be used alone It can be used as an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter in various compositions such as pharmaceuticals, quasi-drugs, food and drink, and cosmetics. As a result, a composition having an epidermal cell activating action, an epidermal cell growth factor production promoting action, and an epidermal cell growth factor receptor production promoting action can be obtained.
ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を含有することを特徴とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤は、その形態およびその他成分の配合の有無等については、なんら制限されない。形態については、液状、ペースト状、ゲル状、固体状、粉末状等の任意の形態を、その用途等に応じて選択でき、その形態とするために必要なビヒクル(賦形剤)、溶剤、その他の一般的な添加剤(酸化防止剤、着色剤、分散剤等)を任意に含むことができる。 An epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter characterized by containing one or two selected from purple extract and valerian extract, and the presence or absence of other ingredients, etc., are not limited at all. Regarding the form, any form such as liquid, paste, gel, solid, powder, etc. can be selected according to the application, etc., and the vehicle (excipient), solvent, Other common additives (antioxidants, colorants, dispersants, etc.) can optionally be included.
ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を含有することを特徴とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤を配合する組成物は、任意の剤型をとることができる。組成物が皮膚化粧料、毛髪用化粧料、洗浄料等の場合には、ローションなどの可溶化系やカラミンローション等の分散系、クリームや乳液などの乳化系として提供することができる。さらに、噴射剤と共に充填するエアゾール形態、軟膏剤、パップ剤などの種々の剤型で提供することができる。 A composition containing an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter, characterized by containing one or two selected from purple extract and valerian extract. The product can take any dosage form. When the composition is a skin cosmetic, hair cosmetic, cleanser or the like, it can be provided as a solubilized system such as lotion, a dispersed system such as calamine lotion, or an emulsified system such as cream or milky lotion. Furthermore, it can be provided in various dosage forms such as an aerosol form filled with a propellant, an ointment, and a poultice.
具体的には、乳液、クリーム、ローション、化粧水、パック、美容液、洗浄料、メイクアップ化粧料等の各種化粧料;液剤、軟膏、粉末、顆粒、エアゾール剤、貼付剤、パップ剤等の様々な形態の化粧料、医薬部外品や外用医薬品などが例示できる。 Specifically, various cosmetics such as emulsions, creams, lotions, lotions, packs, serums, cleansers, and make-up cosmetics; Various forms of cosmetics, quasi-drugs, topical drugs, and the like can be exemplified.
また、経口用医薬品等の場合には、ドリンク剤・点滴剤などの液剤、ガム・飴のような固形剤、カプセル、粉末、顆粒、錠剤などの一般的な剤型とすることができる。 In the case of oral pharmaceuticals, general dosage forms such as liquids such as drinks and infusions, solids such as gums and candies, capsules, powders, granules, and tablets can be used.
ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を含有することを特徴とするムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種を配合する組成物には、これらの他に、その用途と必要に応じて、医薬品、医薬部外品、皮膚化粧料、毛髪用化粧料、洗浄料、および経口用医薬品等に通常配合される任意の成分、例えば水、油性成分、保湿剤、粉体、色素、乳化剤、可溶化剤、ゲル化剤、洗浄剤、紫外線吸収剤、抗炎症剤、増粘剤、pH調整剤、キレート剤、薬剤(薬効成分)、香料、樹脂、防菌防かび剤、抗酸化剤、アルコール類等を適宜配合することができる。さらに、本発明の効果を損なわない範囲において、他の保湿剤、抗老化剤、美白剤、抗酸化剤および痩身剤あるいは各種植物/菌類またはその抽出物との併用も可能である。 A composition containing one or two selected from a purple extract and a valerian extract characterized by containing one or two selected from a purple extract and a valerian extract, these In addition, depending on the application and need, optional ingredients that are usually blended in pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics, cleansers, and oral pharmaceuticals, such as water, oily ingredients, Humectants, powders, pigments, emulsifiers, solubilizers, gelling agents, detergents, UV absorbers, anti-inflammatory agents, thickeners, pH adjusters, chelating agents, drugs (medicinal ingredients), fragrances, resins, Antibacterial and antifungal agents, antioxidants, alcohols and the like can be appropriately added. Furthermore, other moisturizing agents, anti-aging agents, whitening agents, antioxidants, slimming agents, various plants/fungi, or extracts thereof can be used in combination, as long as the effects of the present invention are not impaired.
ムラサキ抽出物、カノコソウ抽出物から選択される1種又は2種の種々の組成物への配合量は、組成物の種類や目的等によって調整することができるが、効果や安定性などの点から、全量に対して、0.0001~10.0質量%が好ましく、より好ましくは、0.001~5.0質量%であり、さらに好ましくは0.01~5.0質量%である。 The amount of one or two selected from purple extract and valerian extract in various compositions can be adjusted depending on the type and purpose of the composition, but from the viewpoint of effect and stability. , preferably 0.0001 to 10.0% by mass, more preferably 0.001 to 5.0% by mass, still more preferably 0.01 to 5.0% by mass, based on the total amount.
以下、実施例により本発明を具体的に説明するが、これにより本発明の範囲が限定されるものではない。 EXAMPLES The present invention will be specifically described below with reference to examples, but the scope of the present invention is not limited by these examples.
[ムラサキ抽出物1]
ムラサキ(Lithospermum officinale)の根を乾燥後細切し、20質量倍量のエタノール/BG混液(9:1)に浸漬し、ろ過後ろ液を採取し、溶媒を留去し、ムラサキ抽出物1とした。
[Purple extract 1]
After drying, the roots of purple (Lithospermum officinale) were cut into small pieces, immersed in a 20-fold mass ethanol/BG mixture (9:1), the filtrate was collected, the solvent was distilled off, and purple extract 1 was obtained. bottom.
[ムラサキ抽出物2]
ムラサキ抽出物1をグリセリン/エタノール混液(25:75)溶液にて1質量%濃度となるよう溶解後熟成し、再度ろ過したものをムラサキ抽出物2とした。
[Murasaki extract 2]
Murasaki extract 1 was dissolved in a glycerin/ethanol mixed solution (25:75) to a concentration of 1% by mass, aged, and filtered again to obtain Murasaki extract 2.
[カノコソウ抽出物1]
カノコソウの根及び根茎を乾燥後細切し、20質量倍量の精製水に浸漬し、ろ過後ろ液を採取し、溶媒を留去し、カノコソウ抽出物1とした。
[Valeriana extract 1]
After drying, the roots and rhizomes of valerian were finely chopped, immersed in 20 times the mass of purified water, the filtrate was collected, and the solvent was distilled off to obtain valerian extract 1.
[カノコソウ抽出物2]
カノコソウ抽出物1を20質量%1,3-ブチレングリコール水溶液溶解後熟成し、再度ろ過したものをカノコソウ抽出物2とした。
[Valeriana extract 2]
Valerian extract 1 was dissolved in a 20% by mass 1,3-butylene glycol aqueous solution, aged, and filtered again to obtain valerian extract 2.
[表皮角化細胞賦活作用]
クラボウ社(倉敷紡績株式会社)製正常ヒト表皮角化細胞を、1ウェル当たり2.0×104個となるように96ウェルマイクロプレートに播種した。播種培地には、市販のHumedia KG2(クラボウ社製)を用いた。24時間培養後、各濃度となるように試料(抽出物)を添加したHumedia KG2に交換し、さらに24時間培養した。上清を除いた後、3-(4,5-ジメチル-2-チアゾリル)-2,5-ジフェニルテトラゾリウムブロミド(MTT)を100μg/mL含有する培地に交換して約1時間培養した。その後、テトラゾリウム環の開環により生じるフォルマザンを2-プロパノールにて抽出し、マイクロプレートリーダーにて550nmの吸光度を測定した。同時に、濁度として650nmにおける吸光度を測定し、両測定値の差により細胞賦活作用を評価した。評価では、試料を含む培地の他に、コントロールとしてHumedia KG2を用いた。結果を表1、表2に示した。
[Epidermal keratinocyte activating action]
Normal human epidermal keratinocytes manufactured by Kurabo Co., Ltd. (Kurashiki Boseki Co., Ltd.) were seeded in a 96-well microplate at 2.0×10 4 per well. Commercially available Humedia KG2 (manufactured by Kurabo Industries) was used as a seeding medium. After culturing for 24 hours, the cells were replaced with Humedia KG2 to which the sample (extract) was added at each concentration, and cultured for another 24 hours. After removing the supernatant, the medium was replaced with a medium containing 100 μg/mL of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) and cultured for about 1 hour. Thereafter, formazan produced by opening the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured using a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the difference between the two measured values was used to evaluate the cell activation action. Humedia KG2 was used as a control in addition to the medium containing the sample in the evaluation. The results are shown in Tables 1 and 2.
表1、2に示した通り、ムラサキ抽出物1、カノコソウ抽出物1は、濃度依存的に表皮角化細胞の賦活作用が認められていた。 As shown in Tables 1 and 2, purple extract 1 and valerian extract 1 were found to have an activation effect on epidermal keratinocytes in a concentration-dependent manner.
[表皮細胞成長因子産生促進作用、表皮細胞成長因子受容体産生促進作用]
ヒト表皮角化細胞を5×105個/ウェルとなるように6ウェルプレートに播種し、Humedia KG2培地にて一晩培養した。植物抽出物を溶解した培地に交換し、37℃、5% CO2インキュベーター内で24時間培養した。細胞からのTotal RNA抽出はTrizol reagentを用い、ライフテクノロジーズ社のプロトコールに従って調製した。cDNA合成後に下記のプライマーを使用してサイバーグリーン法によるリアルタイムPCRにより遺伝子発現を確認した。内部標準としてGAPDHを使用した。結果を表4に示す。
[Epidermal Growth Factor Production Promoting Action, Epidermal Growth Factor Receptor Production Promoting Action]
Human epidermal keratinocytes were seeded in a 6-well plate at 5×10 5 cells/well and cultured overnight in Humedia KG2 medium. The medium in which the plant extract was dissolved was replaced and cultured for 24 hours in a 37°C, 5% CO2 incubator. Total RNA was extracted from the cells using Trizol reagent and prepared according to the Life Technologies protocol. After cDNA synthesis, gene expression was confirmed by real-time PCR by the Cybergreen method using the following primers. GAPDH was used as an internal standard. Table 4 shows the results.
表4に示した通りムラサキ抽出物1、カノコソウ抽出物1は、高い表皮細胞成長因子産生促進作用、および表皮細胞成長因子受容体産生促進作用を示した。 As shown in Table 4, purple extract 1 and valerian extract 1 exhibited high epidermal growth factor production-promoting action and epidermal growth factor receptor production-promoting action.
[実施例1]乳液
(1)スクワラン 10.0(質量%)
(2)メチルフェニルポリシロキサン 4.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)モノステアリン酸ポリオキシエチレン
ソルビタン(20E.O.) 1.3
(6)モノステアリン酸ソルビタン 1.0
(7)グリセリン 4.0
(8)パラオキシ安息香酸メチル 0.1
(9)カルボキシビニルポリマー 0.15
(10)精製水 100とする残部
(11)アルギニン(1質量%水溶液) 20.0
(12)ムラサキ抽出物2 1.0
製法:(1)~(6)の油相成分を80℃にて加熱溶解する。一方(7)~(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。冷却後40℃にて、(11)と(12)を順次加え、均一に混合する。
[Example 1] Emulsion (1) Squalane 10.0 (mass%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20 E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) carboxyvinyl polymer 0.15
(10) Remainder of purified water 100 (11) Arginine (1% by mass aqueous solution) 20.0
(12) Murasaki extract 2 1.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80°C. On the other hand, the water phase components (7) to (10) are heated and dissolved at 80°C. The oil phase components are added to this while stirring, and uniformly emulsified with a homogenizer. After cooling, at 40° C., (11) and (12) are sequentially added and uniformly mixed.
[実施例2]化粧水
(1)エタノール 15.0(質量%)
(2)ポリオキシエチレン(40E.O.)硬化ヒマシ油 0.3
(3)香料 0.1
(4)精製水 100とする残部
(5)クエン酸 0.02
(6)クエン酸ナトリウム 0.1
(7)グリセリン 1.0
(8)ヒドロキシエチルセルロース 0.1
(9)カノコソウ抽出物2 1.0
製法:(1)に(2)および(3)を溶解する。さらに(4)~(8)を順次添加した後、十分に攪拌し、(9)を加え、均一に混合する。
[Example 2] Lotion (1) Ethanol 15.0 (mass%)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Perfume 0.1
(4) Remainder of purified water 100 (5) Citric acid 0.02
(6) sodium citrate 0.1
(7) Glycerin 1.0
(8) hydroxyethyl cellulose 0.1
(9) valerian extract 2 1.0
Preparation method: (2) and (3) are dissolved in (1). Further, after sequentially adding (4) to (8), the mixture is sufficiently stirred, and (9) is added and mixed uniformly.
[実施例3]クリーム
(1)スクワラン 10.0(質量%)
(2)ステアリン酸 2.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)セタノール 3.6
(6)親油型モノステアリン酸グリセリン 2.0
(7)グリセリン 10.0
(8)パラオキシ安息香酸メチル 0.1
(9)アルギニン(20質量%水溶液) 15.0
(10)精製水 100とする残部
(11)カルボキシビニルポリマー(1質量%水溶液) 15.0
(12)ムラサキ抽出物2 0.5
製法:(1)~(6)の油相成分を80℃にて加熱溶解する。一方(7)~(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。(11)を添加して攪拌後、冷却し40℃にて(12)を加え、均一に混合する。
[Example 3] Cream (1) Squalane 10.0 (% by mass)
(2) stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by mass aqueous solution) 15.0
(10) Remainder of purified water 100 (11) Carboxyvinyl polymer (1% by mass aqueous solution) 15.0
(12) Murasaki extract 2 0.5
Production method: The oil phase components (1) to (6) are heated and dissolved at 80°C. On the other hand, the water phase components (7) to (10) are heated and dissolved at 80°C. The oil phase components are added to this while stirring, and uniformly emulsified with a homogenizer. After (11) is added and stirred, the mixture is cooled, and (12) is added at 40° C. and mixed uniformly.
[実施例4]美容液
(1)精製水 100とする残部(質量%)
(2)グリセリン 10.0
(3)ショ糖脂肪酸エステル 1.3
(4)カルボキシビニルポリマー(1質量%水溶液) 17.5
(5)アルギン酸ナトリウム(1質量%水溶液) 15.0
(6)モノラウリン酸ポリグリセリル 1.0
(7)マカデミアナッツ油脂肪酸フィトステリル 3.0
(8)N-ラウロイル-L-グルタミン酸
ジ(フィトステリル-2-オクチルドデシル) 2.0
(9)硬化パーム油 2.0
(10)スクワラン(オリーブ由来) 1.0
(11)ベヘニルアルコール 0.75
(12)ミツロウ 1.0
(13)ホホバ油 1.0
(14)1,3-ブチレングリコール 10.0
(15)L-アルギニン(10質量%水溶液) 2.0
(16)カノコソウ抽出物2 0.3
製法:(1)~(6)の水相成分を混合し、75℃にて加熱溶解する。一方、(7)~(14)の油相成分を混合し、75℃にて加熱溶解する。次いで、上記水相成分に油相成分を添加して予備乳化を行った後、ホモミキサーにて均一に乳化する。冷却後50℃にて(15)を、40℃にて(16)を加え、均一に混合する。
[Example 4] Essence (1) Remainder of purified water 100 (% by mass)
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by mass aqueous solution) 17.5
(5) Sodium alginate (1% by mass aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di(phytosteryl-2-octyldodecyl) 2.0
(9) Hydrogenated palm oil 2.0
(10) Squalane (derived from olive) 1.0
(11) behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10 wt% aqueous solution) 2.0
(16) valerian extract 2 0.3
Production method: The water phase components (1) to (6) are mixed and dissolved by heating at 75°C. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75°C. Next, the oil phase component is added to the water phase component and pre-emulsified, followed by uniform emulsification with a homomixer. After cooling, add (15) at 50°C and add (16) at 40°C, and mix uniformly.
[実施例5]水性ジェル
(1)カルボキシビニルポリマー 0.5(質量%)
(2)精製水 100とする残部
(3)水酸化ナトリウム(10質量%水溶液) 0.5
(4)グリセリン 10.0
(5)1,3-ブチレングリコール 10.0
(6)エタノール 10.0
(7)パラオキシ安息香酸メチル 0.1
(8)香料 0.1
(9)ムラサキ抽出物2 0.3
(10)カノコソウ抽出物2 0.3
(11)ポリオキシエチレン(60E.O.)硬化ヒマシ油 1.0
製法:(1)を(2)に加え、均一に攪拌した後、(3)を加える。均一に攪拌した後、(4)に予め溶解した(5)を加える。均一に攪拌した後、予め混合しておいた(6)~(11)を加え、均一に攪拌混合する。
[Example 5] Aqueous gel (1) Carboxyvinyl polymer 0.5 (mass%)
(2) Remaining purified water 100 (3) Sodium hydroxide (10% by mass aqueous solution) 0.5
(4) Glycerin 10.0
(5) 1,3-butylene glycol 10.0
(6) Ethanol 10.0
(7) methyl paraoxybenzoate 0.1
(8) Perfume 0.1
(9) Murasaki extract 2 0.3
(10) valerian extract 2 0.3
(11) Polyoxyethylene (60E.O.) hydrogenated castor oil 1.0
Production method: Add (1) to (2), stir uniformly, and then add (3). After uniformly stirring, (5) dissolved in advance in (4) is added. After uniformly stirring, (6) to (11) mixed in advance are added and uniformly stirred and mixed.
Claims (2)
細胞成長因子産生促進剤(カイネチンとシコンエキスを併用して含有する化粧品を除く)。 An epidermal cell growth factor production promoter containing one or two selected from purple extract and valerian extract as active ingredients (excluding cosmetics containing both kinetin and lichen extract).
細胞成長因子受容体産生促進剤(カイネチンとシコンエキスを併用して含有する化粧品を除く)。 An epidermal growth factor receptor production-enhancing agent containing, as active ingredients, one or two selected from purple extract and valerian extract (excluding cosmetics containing both kinetin and lichen extract).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016213669A JP7246125B2 (en) | 2016-10-31 | 2016-10-31 | Epidermal cell activator |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016213669A JP7246125B2 (en) | 2016-10-31 | 2016-10-31 | Epidermal cell activator |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018070524A JP2018070524A (en) | 2018-05-10 |
JP7246125B2 true JP7246125B2 (en) | 2023-03-27 |
Family
ID=62113846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016213669A Active JP7246125B2 (en) | 2016-10-31 | 2016-10-31 | Epidermal cell activator |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7246125B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7241483B2 (en) * | 2018-07-23 | 2023-03-17 | 株式会社ノエビア | skin composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003335619A (en) | 2002-05-14 | 2003-11-25 | Noevir Co Ltd | Skin care preparation for external use |
JP6019709B2 (en) | 2012-04-25 | 2016-11-02 | ブラザー工業株式会社 | Developer container |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019709A (en) * | 1983-07-14 | 1985-01-31 | Tsunetaka Yokoyama | Preparation of cosmetic for preventing aging of skin and promoting cell division |
JP3534945B2 (en) * | 1996-05-28 | 2004-06-07 | カネボウ株式会社 | Skin cosmetics |
-
2016
- 2016-10-31 JP JP2016213669A patent/JP7246125B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003335619A (en) | 2002-05-14 | 2003-11-25 | Noevir Co Ltd | Skin care preparation for external use |
JP6019709B2 (en) | 2012-04-25 | 2016-11-02 | ブラザー工業株式会社 | Developer container |
Also Published As
Publication number | Publication date |
---|---|
JP2018070524A (en) | 2018-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4299374B2 (en) | Cell activator and its application | |
JP2007051087A (en) | Collagen production promoter, skin care external preparation and oral medicine using the same | |
JP5773111B2 (en) | Composition for inhibiting skin pigmentation and use thereof | |
JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
JP7246125B2 (en) | Epidermal cell activator | |
JP2008303147A (en) | External preparation for skin | |
WO2014010657A1 (en) | Processed nutmeg product and method for producing same | |
JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
JP2007176878A (en) | NF-kappaB ACTIVATION INHIBITOR AND EXTERNAL PREPARATION COMPOSITION I CONTAINING THE SAME | |
JP2005008548A (en) | External preparation for skin | |
JP4083111B2 (en) | β-endorphin production promoter | |
JP6723979B2 (en) | Wrinkle improver | |
JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
JP2011246354A (en) | Skin external preparation | |
JP2004026697A (en) | Cell-activating agent, anti-oxidizing agent, melamine production inhibitor and skin care preparation for external use | |
JP2011051920A (en) | Bleaching agent | |
JP5171752B2 (en) | Topical skin preparation | |
JP2008303180A (en) | Skin-lightening agent, skincare preparation for external use, and functional oral composition | |
JP6017259B2 (en) | Endothelin action inhibitor | |
JPH09157151A (en) | Melanin generation inhibitor and whitening agent | |
JP4994684B2 (en) | Moisturizer, cell activator, and antioxidant | |
JP5144048B2 (en) | Radical scavenger, antioxidant skin external preparation, and radical scavenging method | |
WO2008035572A1 (en) | Moisturizing agent, anti-aging agent, skin-whitening agent, antiinflammatory agent, and antioxidant agent | |
JP2006176425A (en) | Collagen production promoter and skin care preparation | |
JP2023000167A (en) | Topical preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190712 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200824 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210107 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210406 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220614 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220906 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230110 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20230214 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20230314 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20230314 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230314 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7246125 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |